Alembic Pharmaceuticals

Alembic Pharmaceuticals
Alembic Pharmaceuticals
Shareholder Return: 3-year average, Sales Growth: 3-year Compounded Annual Growth Rate, Return On Equity: 3-year Return on Equity.
At a Glance
  • Shareholder Return
    454%
  • Sales Growth
    27%
  • Return on Equity
    45 %

Why Super 50

Shift in focus from commodity APIs to higher potential formulations. A strong supply chain to build customer trust. Increasing investment in R&D.



More Stories

X